Dr. Tong Wang, Chief Scientific Officer of Shengshi Taikang, has been selected as a "Double Innovation Talent" in Jiangsu Province.

Currently, Senglitin (formerly known as Shenglitin), a next-generation, highly selective DPP-4 inhibitor developed entirely in-house, is on the verge of receiving regulatory approval and entering the market. Clinical trials have shown that, compared to existing similar drugs, Senglitin delivers twice the therapeutic efficacy at half the dose, positioning it as a potentially best-in-class medication for blood sugar control. Even more remarkable, its exceptional safety profile effectively addresses common adverse effects often associated with currently available treatments. Among the oncology candidates advancing into clinical stages, CGT-1881—a CXCR4 antagonist designed for hematopoietic stem cell mobilization—is the only original small-molecule, orally administered CXCR4 inhibitor of its kind in China. Meanwhile, CGT-6321, a dual-target inhibitor targeting both FGFR and VEGFR, holds promise as a potential "first-in-class" therapy for solid tumors. Building on the success of the CGT-6321 program, the company’s executive team—led by Dr. Tong Wang—was recently honored with the prestigious 2022 Gusu Leading Talent Award for the most innovative and impactful innovation team of the year.

Jiangsu Province's Dual Innovation Talent Program focuses on attracting high-caliber entrepreneurial and innovative talent—both individuals and teams—aligned with the province's priority industries. The initiative aims to accelerate the commercialization and industrialization of groundbreaking scientific and technological achievements backed by independent intellectual property rights, nurture a pipeline of fast-growing, technology-driven enterprises, and help leading-edge high-tech firms secure global recognition by pioneering breakthroughs in core technologies and cutting-edge products. Ultimately, the program seeks to establish robust clusters of rapidly advancing, competitively superior high-tech products and companies.

CSO Dr. Wang Tong communicates with CEO Dr. Yu Qiang and the R&D team about development progress.

Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taikang, brings over two decades of comprehensive experience in drug discovery and development, as well as pharmaceutical R&D management, gained from leading U.S. biopharmaceutical companies and research institutions. A strategic scientist with a proven track record of breaking through critical technologies, pioneering emerging disciplines, and driving innovation in the pharmaceutical industry, Dr. Wang has been recognized at various levels since joining Shengshi Taikang—earning prestigious titles as a science and technology leader. Her contributions have not only infused the company with groundbreaking ideas and cutting-edge technological approaches but have also enabled the seamless integration and establishment of a robust, end-to-end platform for new drug development and commercialization. Under her leadership, the company’s R&D team is rapidly advancing its pipeline of innovative drug candidates, with several promising products already poised to enter clinical trials or soon reach the commercialization stage.

Currently, the next-generation, highly selective DPP-4 inhibitor Senglitin (formerly known as Shenglitin), developed entirely in-house, is on the verge of receiving regulatory approval and hitting the market. Clinical trials have demonstrated that, compared to existing同类 drugs, Senglitin delivers twice the therapeutic efficacy with half the dose, positioning it as a potentially best-in-class medication for blood sugar control. Even more remarkable, its exceptional safety profile addresses common adverse effects often seen with currently available products. Among the oncology candidates advancing into clinical stages, CGT-1881—a CXCR4 antagonist designed for hematopoietic stem cell mobilization—is the only original small-molecule, orally administered CXCR4 inhibitor of its kind in China. Meanwhile, CGT-6321, a dual-target inhibitor targeting both FGFR and VEGFR, holds promise as a potential "first-in-class" therapy for solid tumors. Building on the success of the CGT-6321 program, the company’s executive team—led by Dr. Tong Wang—was recently honored with the prestigious 2022 Gusu Leading Talent Award for the most innovative and impactful innovation team of the year.

Shengshi Taikе is a biotechnology company in the commercialization phase, with its lead product—a Class 1 innovative drug called Senglitin—poised for imminent market launch. Founded in 2010 in Suzhou Industrial Park, the company boasts a core team that brings decades of global experience across the entire lifecycle of pharmaceutical products. Shengshi Taikе is dedicated to the research, development, and industrialization of high-quality, differentiated small-molecule innovative drugs. Leveraging an integrated drug R&D technology platform and a diverse business perspective, the company has built a robust pipeline of cutting-edge therapies spanning areas such as blood sugar control, cancer treatment, and autoimmune diseases.